Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > march trade sum?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Apr 01, 2021 3:09pm
162 Views
Post# 32924432

RE:march trade sum?

RE:march trade sum?

RBC was the main buyer buy a mile, fallow by mackie ( interestingly) Anon at the bottom but is misleading ..

House Positions for PMN.TO 
 
From:  To:  

22,635,346 ($3,532,828) PMN.TO shares exchanged hands from Mon Mar 01 2021 to Tue Mar 30 2021.
House  Bought  Sold  Net 
House 002
RBC
Bought $1,029,912
Volume 6,509,703
Average $0.158
Sold $472,143
Volume 2,945,624
Average $0.160
Net $557,769
Volume 3,564,079
 
House 083
Mackie
Bought $178,295
Volume 1,284,000
Average $0.139
Sold $22,600
Volume 150,000
Average $0.151
Net $155,695
Volume 1,134,000
 
House 079
CIBC
Bought $188,267
Volume 1,125,084
Average $0.167



M101 wrote: Is there some buy program protecting 20 cents today? This is a stubborn rally, I'm sure there remain 10s of millions of shares hanging over the sell side and yet no one seems to want to chase it down.  They had no problem chasing it down all fall, and every fall, when they knew Goldstein was going to reward them with even more free warrants.  
Will someone here please post the March net trade under Anonymous? 
(cause I quit stockwatch)


 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities